Organometallics p. 3777 - 3781 (2001)
Update date:2022-07-29
Topics:
Zhang, Qian-Feng
Cheung, Florence K.M.
Wong, Wai-Yeung
Williams, Ian D.
Leung, Wa-Hung
Treatment of [Cp*Ru(NO)Cl2] (Cp* = η5-C5Me5) with NaQAr or LiQAr (Q = S, Se, Te; Ar = C6F4H or Ph) affords [Cp*Ru(NO)(QAr)2]. Interactions of [Cp*Ru(NO)(SC6F4H)2] with PR3 (R = Ph or Me) give [Cp*Ru(PR3)2(SC6 F4H)] via phosphoraminate intermediates. The crystal structures of [Cp*Ru(NO)(SC6F4H)2] and [Cp*Ru(PMe3)2(SC6F4H)] have been determined. Treatment of [Cp*Ru(MeCN)3][PF6] with HN[SeP(i-Pr)2]2 affords a novel Cp*Ru(IV) complex, [Cp*Ru{η2-Se2P(i-Pr)2} {η2-SeP(i-Pr)2}][PF6], which has been characterized by X-ray crystallography.
Huangshan Honghui Pharm Technology Co., Ltd.(expird)
website:http://www.honghuichem.com
Contact:18855958372
Address:Qingshan Wan No.1,Nanyuan Kou,SheXian Huangshan City,Anhui Province
Xi'an Costrong Pharmaceutical Co., Ltd.
Contact:029- 68576496
Address:Room 2004,Shuibao Building,No.190,South Erhuan Rd, Yanta District,Xi'an,Shaan Xi,China
Linyi Shengxin Pharmaceutical R&D Co., Ltd
Contact:+86-18653953873
Address:West First of Yufeng Road, Yishui County
Hangzhou Taiyan Trading Co., Ltd(expird)
Contact:+86-13777583958
Address:NO.63, Xingyi Street, Xihu District, Hangzhou, Zhejiang, China
Contact:021-36356756
Address:Room601,Building No.14,280 Yangcheng Road,Shanghai
Doi:10.1248/cpb.35.4990
(1987)Doi:10.1021/ol0521228
(2005)Doi:10.1007/BF00855672
()Doi:10.1016/j.bmcl.2015.10.093
(2015)Doi:10.1016/S0040-4039(01)97095-9
(1971)Doi:10.1080/07391102.2020.1846621
(2020)
